GH Research (NASDAQ:GHRS) Shares Up 2.8% – Still a Buy?

GH Research PLC (NASDAQ:GHRS) shares were up 2.8% during mid-day trading on Wednesday . The company traded as high as $8.33 and last traded at $8.33. Approximately 3,888 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 79,718 shares. The stock had previously closed at $8.10.

Analyst Ratings Changes

Several analysts recently commented on the stock. JMP Securities restated a “market outperform” rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Thursday, September 5th.

GH Research Trading Up 7.3 %

The company’s fifty day simple moving average is $8.09 and its 200-day simple moving average is $10.55. The stock has a market cap of $452.14 million, a P/E ratio of -12.36 and a beta of 0.79.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, analysts expect that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research makes up approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th largest holding. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).